Overview

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Neonates and Infants

Status:
Recruiting
Trial end date:
2024-08-31
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to understand the pharmacokinetics (PK) of single and multiple doses of cefiderocol in children from birth to less than 3 months of age with suspected or confirmed aerobic Gram-negative bacterial infections.
Phase:
Phase 2
Details
Lead Sponsor:
Shionogi
Treatments:
Cefiderocol